File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.cjca.2018.08.013
- Scopus: eid_2-s2.0-85055999361
- PMID: 30414702
- WOS: WOS:000452275800012
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis
Title | Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis |
---|---|
Authors | |
Keywords | all cause mortality blood pressure regulation cardiovascular disease cardiovascular mortality cerebrovascular accident |
Issue Date | 2018 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.onlinecjc.ca/ |
Citation | Canadian Journal of Cardiology, 2018, v. 34 n. 12, p. 1581-1589 How to Cite? |
Abstract | Background: There is clinical trial evidence that lowering systolic blood pressure (SBP) to < 120 mm Hg is beneficial, and this has influenced the latest American guideline on hypertension. We therefore used network meta-analysis to study the association between SBP and cardiovascular outcomes.
Methods: We searched for randomized controlled trials targeting different blood pressure levels that reported cardiovascular events. The mean achieved SBP in each trial was classified into 5 groups (110-119, 120-129, 130-139, 140-149, and 150-159 mm Hg). The primary variables of cardiovascular mortality, stroke, and myocardial infarction were assessed using frequentist and Bayesian approaches.
Results: Fourteen trials with altogether 44,015 patients were included. Stroke and major adverse cardiovascular events were reduced when lowering SBP to 120-129 mm Hg compared with 130-139 mm Hg (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.69-0.99 and OR 0.84, 95% CI 0.73-0.96), 140-149 mm Hg (OR 0.73, 95% CI 0.55-0.97 and OR 0.74, 95% CI 0.60-0.90), and 150-159 mm Hg (OR 0.43, 95% CI 0.26-0.71 and OR 0.41, 95% CI 0.30-0.57), respectively. More intensive control to < 120 mm Hg further reduced stroke (OR 0.58, 95% CI 0.38-0.87; OR 0.51, 95% CI 0.32-0.81; and OR 0.30, 95% CI 0.16-0.56). In contrast, SBP ≥ 150 mm Hg increased myocardial infarction and cardiovascular mortality compared with 120-129 mm Hg (OR 1.73, 95% CI 1.06-2.82 and OR 2.18, 95% CI 1.32-3.59) and 130-139 mm Hg (OR 1.53, 95% CI 1.01-2.32 and OR 1.71, 95% CI 1.11-2.61). No significant relationship between SBP and all-cause mortality was found.
Conclusions; SBP < 130 mm Hg is associated with a lower risk of stroke and major adverse cardiovascular events. Further lowering to < 120 mm Hg can be considered to reduce stroke risk if the therapy is tolerated. Long-term SBP should not exceed 150 mm Hg because of the increased risk of myocardial infarction and cardiac deaths. |
Persistent Identifier | http://hdl.handle.net/10722/273951 |
ISSN | 2023 Impact Factor: 5.8 2023 SCImago Journal Rankings: 1.666 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fei, Y | - |
dc.contributor.author | Tsoi, MF | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2019-08-18T14:52:01Z | - |
dc.date.available | 2019-08-18T14:52:01Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Canadian Journal of Cardiology, 2018, v. 34 n. 12, p. 1581-1589 | - |
dc.identifier.issn | 0828-282X | - |
dc.identifier.uri | http://hdl.handle.net/10722/273951 | - |
dc.description.abstract | Background: There is clinical trial evidence that lowering systolic blood pressure (SBP) to < 120 mm Hg is beneficial, and this has influenced the latest American guideline on hypertension. We therefore used network meta-analysis to study the association between SBP and cardiovascular outcomes. Methods: We searched for randomized controlled trials targeting different blood pressure levels that reported cardiovascular events. The mean achieved SBP in each trial was classified into 5 groups (110-119, 120-129, 130-139, 140-149, and 150-159 mm Hg). The primary variables of cardiovascular mortality, stroke, and myocardial infarction were assessed using frequentist and Bayesian approaches. Results: Fourteen trials with altogether 44,015 patients were included. Stroke and major adverse cardiovascular events were reduced when lowering SBP to 120-129 mm Hg compared with 130-139 mm Hg (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.69-0.99 and OR 0.84, 95% CI 0.73-0.96), 140-149 mm Hg (OR 0.73, 95% CI 0.55-0.97 and OR 0.74, 95% CI 0.60-0.90), and 150-159 mm Hg (OR 0.43, 95% CI 0.26-0.71 and OR 0.41, 95% CI 0.30-0.57), respectively. More intensive control to < 120 mm Hg further reduced stroke (OR 0.58, 95% CI 0.38-0.87; OR 0.51, 95% CI 0.32-0.81; and OR 0.30, 95% CI 0.16-0.56). In contrast, SBP ≥ 150 mm Hg increased myocardial infarction and cardiovascular mortality compared with 120-129 mm Hg (OR 1.73, 95% CI 1.06-2.82 and OR 2.18, 95% CI 1.32-3.59) and 130-139 mm Hg (OR 1.53, 95% CI 1.01-2.32 and OR 1.71, 95% CI 1.11-2.61). No significant relationship between SBP and all-cause mortality was found. Conclusions; SBP < 130 mm Hg is associated with a lower risk of stroke and major adverse cardiovascular events. Further lowering to < 120 mm Hg can be considered to reduce stroke risk if the therapy is tolerated. Long-term SBP should not exceed 150 mm Hg because of the increased risk of myocardial infarction and cardiac deaths. | - |
dc.language | eng | - |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.onlinecjc.ca/ | - |
dc.relation.ispartof | Canadian Journal of Cardiology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | all cause mortality | - |
dc.subject | blood pressure regulation | - |
dc.subject | cardiovascular disease | - |
dc.subject | cardiovascular mortality | - |
dc.subject | cerebrovascular accident | - |
dc.title | Determining the Optimal Systolic Blood Pressure for Hypertensive Patients: A Network Meta-analysis | - |
dc.type | Article | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1016/j.cjca.2018.08.013 | - |
dc.identifier.pmid | 30414702 | - |
dc.identifier.scopus | eid_2-s2.0-85055999361 | - |
dc.identifier.hkuros | 302216 | - |
dc.identifier.volume | 34 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1581 | - |
dc.identifier.epage | 1589 | - |
dc.identifier.isi | WOS:000452275800012 | - |
dc.publisher.place | Canada | - |
dc.identifier.issnl | 0828-282X | - |